Myasthenia gravis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 5: Line 5:
==Natural History==
==Natural History==
The [[age of onset]] in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is [[female]] predominant and the late type (after age of 60) is [[male]] predominant. Between the age of 50-60 there is no significant different between [[male]] and [[female]].<ref name="pmid23893883">{{cite journal |vauthors=Alkhawajah NM, Oger J |title=Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing |journal=Muscle Nerve |volume=48 |issue=5 |pages=705–10 |date=November 2013 |pmid=23893883 |doi=10.1002/mus.23964 |url=}}</ref> About 50 percent of patiens have [[ptosis]] and [[diplopia]] as their presenting sign. [[Ptosis]] is usually asymmetrical. The direction and degree of [[diplopia]] may change in a [[Myasthenia gravis|MG]] patients because of [[Fatigue|fatigable]] [[ocular]] motor [[paresis]].<ref name="pmid7369304">{{cite journal |vauthors=Osher RH, Glaser JS |title=Myasthenic sustained gaze fatigue |journal=Am. J. Ophthalmol. |volume=89 |issue=3 |pages=443–5 |date=March 1980 |pmid=7369304 |doi= |url=}}</ref> The hallmark of myasthenia symptoms is Fluctuating [[weakness]] of specific [[Muscle|muscles]] in [[limbs]], [[bulbar]], [[ocular]] and [[respiratory system]] which get worse with activity or using the muscle.<ref name="pmid23117946">{{cite journal |vauthors=Silvestri NJ, Wolfe GI |title=Myasthenia gravis |journal=Semin Neurol |volume=32 |issue=3 |pages=215–26 |date=July 2012 |pmid=23117946 |doi=10.1055/s-0032-1329200 |url=}}</ref><ref name="pmid15052614">{{cite journal |vauthors=Keesey JC |title=Clinical evaluation and management of myasthenia gravis |journal=Muscle Nerve |volume=29 |issue=4 |pages=484–505 |date=April 2004 |pmid=15052614 |doi=10.1002/mus.20030 |url=}}</ref><ref name="pmid6951497">{{cite journal |vauthors=Keesey J, Buffkin D, Kebo D, Ho W, Herrmann C |title=Plasma exchange alone as therapy for myasthenia gravis |journal=Ann. N. Y. Acad. Sci. |volume=377 |issue= |pages=729–43 |date=1981 |pmid=6951497 |doi= |url=}}</ref> Other signs and symptoms include: Gaze paralysis <ref name="pmid570673">{{cite journal |vauthors=Spooner JW, Baloh RW |title=Eye movement fatigue in myasthenia gravis |journal=Neurology |volume=29 |issue=1 |pages=29–33 |date=January 1979 |pmid=570673 |doi= |url=}}</ref>, Photophobia <ref name="pmid228589">{{cite journal |vauthors=Lepore FE, Sanborn GE, Slevin JT |title=Pupillary dysfunction in myasthenia gravis |journal=Ann. Neurol. |volume=6 |issue=1 |pages=29–33 |date=July 1979 |pmid=228589 |doi=10.1002/ana.410060107 |url=}}</ref>, Facial weakness <ref name="pmid86952">{{cite journal |vauthors=Patten BM |title=Myasthenia gravis: review of diagnosis and management |journal=Muscle Nerve |volume=1 |issue=3 |pages=190–205 |date=1978 |pmid=86952 |doi=10.1002/mus.880010304 |url=}}</ref>, Orbicularis oculi weakness <ref name="pmid11781428">{{cite journal |vauthors=Roberts ME, Steiger MJ, Hart IK |title=Presentation of myasthenia gravis mimicking blepharospasm |journal=Neurology |volume=58 |issue=1 |pages=150–1 |date=January 2002 |pmid=11781428 |doi= |url=}}</ref>, tongue weakness, chewing problems and dysphagia <ref name="pmid7779022">{{cite journal |vauthors=De Assis JL, Marchiori PE, Scaff M |title=Atrophy of the tongue with persistent articulation disorder in myasthenia gravis: report of 10 patients |journal=Auris Nasus Larynx |volume=21 |issue=4 |pages=215–8 |date=1994 |pmid=7779022 |doi= |url=}}</ref><ref name="pmid4708458">{{cite journal |vauthors=Oosterhuis H, Bethlem J |title=Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study |journal=J. Neurol. Neurosurg. Psychiatry |volume=36 |issue=2 |pages=244–54 |date=April 1973 |pmid=4708458 |pmc=1083560 |doi= |url=}}</ref>, Respiratory problems <ref name="pmid10561522">{{cite journal |vauthors=Keesey JC |title=Does myasthenia gravis affect the brain? |journal=J. Neurol. Sci. |volume=170 |issue=2 |pages=77–89 |date=November 1999 |pmid=10561522 |doi= |url=}}</ref>, Limbs muscles weakness <ref name="pmid6290881">{{cite journal |vauthors=Jablecki C, Benton A |title=The frequency of muscle involvement in myasthenia gravis correlates with mean muscle temperature |journal=Muscle Nerve |volume=5 |issue=6 |pages=491–2 |date=1982 |pmid=6290881 |doi= |url=}}</ref><ref name="pmid6287911">{{cite journal |vauthors=Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN |title=A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel |journal=Ann. Neurol. |volume=11 |issue=6 |pages=553–69 |date=June 1982 |pmid=6287911 |doi=10.1002/ana.410110603 |url=}}</ref><ref name="pmid1603341">{{cite journal |vauthors=Oh SJ, Kuruoglu R |title=Chronic limb-girdle myasthenia gravis |journal=Neurology |volume=42 |issue=6 |pages=1153–6 |date=June 1992 |pmid=1603341 |doi= |url=}}</ref><ref name="pmid10025802">{{cite journal |vauthors=Nations SP, Wolfe GI, Amato AA, Jackson CE, Bryan WW, Barohn RJ |title=Distal myasthenia gravis |journal=Neurology |volume=52 |issue=3 |pages=632–4 |date=February 1999 |pmid=10025802 |doi= |url=}}</ref>, Fatigue <ref name="pmid9704288">{{cite journal |vauthors=Ochs CW, Bradley RJ, Katholi CR, Byl NN, Brown VM, Jones LL, Shohet JS |title=Symptoms of patients with myasthenia gravis receiving treatment |journal=J Med |volume=29 |issue=1-2 |pages=1–12 |date=1998 |pmid=9704288 |doi= |url=}}</ref>, Pelvic floor weakness <ref name="pmid4843338">{{cite journal |vauthors=Greene LF, Ghosh MK, Howard FM |title=Transurethral prostatic resection in patients with myasthenia gravis |journal=J. Urol. |volume=112 |issue=2 |pages=226–7 |date=August 1974 |pmid=4843338 |doi= |url=}}</ref><ref name="pmid6180793">{{cite journal |vauthors=Wise GJ, Gerstenfeld JN, Brunner N, Grob D |title=Urinary incontinence following prostatectomy in patients with myasthenia gravis |journal=Br J Urol |volume=54 |issue=4 |pages=369–71 |date=August 1982 |pmid=6180793 |doi= |url=}}</ref>.
The [[age of onset]] in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is [[female]] predominant and the late type (after age of 60) is [[male]] predominant. Between the age of 50-60 there is no significant different between [[male]] and [[female]].<ref name="pmid23893883">{{cite journal |vauthors=Alkhawajah NM, Oger J |title=Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing |journal=Muscle Nerve |volume=48 |issue=5 |pages=705–10 |date=November 2013 |pmid=23893883 |doi=10.1002/mus.23964 |url=}}</ref> About 50 percent of patiens have [[ptosis]] and [[diplopia]] as their presenting sign. [[Ptosis]] is usually asymmetrical. The direction and degree of [[diplopia]] may change in a [[Myasthenia gravis|MG]] patients because of [[Fatigue|fatigable]] [[ocular]] motor [[paresis]].<ref name="pmid7369304">{{cite journal |vauthors=Osher RH, Glaser JS |title=Myasthenic sustained gaze fatigue |journal=Am. J. Ophthalmol. |volume=89 |issue=3 |pages=443–5 |date=March 1980 |pmid=7369304 |doi= |url=}}</ref> The hallmark of myasthenia symptoms is Fluctuating [[weakness]] of specific [[Muscle|muscles]] in [[limbs]], [[bulbar]], [[ocular]] and [[respiratory system]] which get worse with activity or using the muscle.<ref name="pmid23117946">{{cite journal |vauthors=Silvestri NJ, Wolfe GI |title=Myasthenia gravis |journal=Semin Neurol |volume=32 |issue=3 |pages=215–26 |date=July 2012 |pmid=23117946 |doi=10.1055/s-0032-1329200 |url=}}</ref><ref name="pmid15052614">{{cite journal |vauthors=Keesey JC |title=Clinical evaluation and management of myasthenia gravis |journal=Muscle Nerve |volume=29 |issue=4 |pages=484–505 |date=April 2004 |pmid=15052614 |doi=10.1002/mus.20030 |url=}}</ref><ref name="pmid6951497">{{cite journal |vauthors=Keesey J, Buffkin D, Kebo D, Ho W, Herrmann C |title=Plasma exchange alone as therapy for myasthenia gravis |journal=Ann. N. Y. Acad. Sci. |volume=377 |issue= |pages=729–43 |date=1981 |pmid=6951497 |doi= |url=}}</ref> Other signs and symptoms include: Gaze paralysis <ref name="pmid570673">{{cite journal |vauthors=Spooner JW, Baloh RW |title=Eye movement fatigue in myasthenia gravis |journal=Neurology |volume=29 |issue=1 |pages=29–33 |date=January 1979 |pmid=570673 |doi= |url=}}</ref>, Photophobia <ref name="pmid228589">{{cite journal |vauthors=Lepore FE, Sanborn GE, Slevin JT |title=Pupillary dysfunction in myasthenia gravis |journal=Ann. Neurol. |volume=6 |issue=1 |pages=29–33 |date=July 1979 |pmid=228589 |doi=10.1002/ana.410060107 |url=}}</ref>, Facial weakness <ref name="pmid86952">{{cite journal |vauthors=Patten BM |title=Myasthenia gravis: review of diagnosis and management |journal=Muscle Nerve |volume=1 |issue=3 |pages=190–205 |date=1978 |pmid=86952 |doi=10.1002/mus.880010304 |url=}}</ref>, Orbicularis oculi weakness <ref name="pmid11781428">{{cite journal |vauthors=Roberts ME, Steiger MJ, Hart IK |title=Presentation of myasthenia gravis mimicking blepharospasm |journal=Neurology |volume=58 |issue=1 |pages=150–1 |date=January 2002 |pmid=11781428 |doi= |url=}}</ref>, tongue weakness, chewing problems and dysphagia <ref name="pmid7779022">{{cite journal |vauthors=De Assis JL, Marchiori PE, Scaff M |title=Atrophy of the tongue with persistent articulation disorder in myasthenia gravis: report of 10 patients |journal=Auris Nasus Larynx |volume=21 |issue=4 |pages=215–8 |date=1994 |pmid=7779022 |doi= |url=}}</ref><ref name="pmid4708458">{{cite journal |vauthors=Oosterhuis H, Bethlem J |title=Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study |journal=J. Neurol. Neurosurg. Psychiatry |volume=36 |issue=2 |pages=244–54 |date=April 1973 |pmid=4708458 |pmc=1083560 |doi= |url=}}</ref>, Respiratory problems <ref name="pmid10561522">{{cite journal |vauthors=Keesey JC |title=Does myasthenia gravis affect the brain? |journal=J. Neurol. Sci. |volume=170 |issue=2 |pages=77–89 |date=November 1999 |pmid=10561522 |doi= |url=}}</ref>, Limbs muscles weakness <ref name="pmid6290881">{{cite journal |vauthors=Jablecki C, Benton A |title=The frequency of muscle involvement in myasthenia gravis correlates with mean muscle temperature |journal=Muscle Nerve |volume=5 |issue=6 |pages=491–2 |date=1982 |pmid=6290881 |doi= |url=}}</ref><ref name="pmid6287911">{{cite journal |vauthors=Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN |title=A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel |journal=Ann. Neurol. |volume=11 |issue=6 |pages=553–69 |date=June 1982 |pmid=6287911 |doi=10.1002/ana.410110603 |url=}}</ref><ref name="pmid1603341">{{cite journal |vauthors=Oh SJ, Kuruoglu R |title=Chronic limb-girdle myasthenia gravis |journal=Neurology |volume=42 |issue=6 |pages=1153–6 |date=June 1992 |pmid=1603341 |doi= |url=}}</ref><ref name="pmid10025802">{{cite journal |vauthors=Nations SP, Wolfe GI, Amato AA, Jackson CE, Bryan WW, Barohn RJ |title=Distal myasthenia gravis |journal=Neurology |volume=52 |issue=3 |pages=632–4 |date=February 1999 |pmid=10025802 |doi= |url=}}</ref>, Fatigue <ref name="pmid9704288">{{cite journal |vauthors=Ochs CW, Bradley RJ, Katholi CR, Byl NN, Brown VM, Jones LL, Shohet JS |title=Symptoms of patients with myasthenia gravis receiving treatment |journal=J Med |volume=29 |issue=1-2 |pages=1–12 |date=1998 |pmid=9704288 |doi= |url=}}</ref>, Pelvic floor weakness <ref name="pmid4843338">{{cite journal |vauthors=Greene LF, Ghosh MK, Howard FM |title=Transurethral prostatic resection in patients with myasthenia gravis |journal=J. Urol. |volume=112 |issue=2 |pages=226–7 |date=August 1974 |pmid=4843338 |doi= |url=}}</ref><ref name="pmid6180793">{{cite journal |vauthors=Wise GJ, Gerstenfeld JN, Brunner N, Grob D |title=Urinary incontinence following prostatectomy in patients with myasthenia gravis |journal=Br J Urol |volume=54 |issue=4 |pages=369–71 |date=August 1982 |pmid=6180793 |doi= |url=}}</ref>.
In 15 percent of [[Myasthenia gravis|MG]] patients the [[Symptom|symptoms]] remain in the area of palpebrae superioris, [[orbicularis oculi]] and [[Oculomotor nerve|oculomotor]] muscles and other [[Symptom|symptoms]] of generalized disease doesn’t occur in them. This kind of myastehnia is [[Ocular myasthenia|OMG]] (ocular myasthenia gravis).(1-2-3-4-5-6 uptodate ocular)


==Complications==
==Complications==
Complications that can develop as a result of myasthenia gravis are:
Complications from the treatment of myasthenia gravis: the side effects of drugs we use in the treatment of myasthenia gravis can become very serious and reduce the quality of life in these patients.


==Prognosis==
==Prognosis==

Revision as of 15:59, 22 June 2018

Myasthenia gravis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myasthenia Gravis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myasthenia gravis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myasthenia gravis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myasthenia gravis natural history, complications and prognosis

CDC on Myasthenia gravis natural history, complications and prognosis

Myasthenia gravis natural history, complications and prognosis in the news

Blogs on Myasthenia gravis natural history, complications and prognosis

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myasthenia gravis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Natural History

The age of onset in Myasthenia gravis follows a bimodal distribution. The early type (before age of 50) is female predominant and the late type (after age of 60) is male predominant. Between the age of 50-60 there is no significant different between male and female.[1] About 50 percent of patiens have ptosis and diplopia as their presenting sign. Ptosis is usually asymmetrical. The direction and degree of diplopia may change in a MG patients because of fatigable ocular motor paresis.[2] The hallmark of myasthenia symptoms is Fluctuating weakness of specific muscles in limbs, bulbar, ocular and respiratory system which get worse with activity or using the muscle.[3][4][5] Other signs and symptoms include: Gaze paralysis [6], Photophobia [7], Facial weakness [8], Orbicularis oculi weakness [9], tongue weakness, chewing problems and dysphagia [10][11], Respiratory problems [12], Limbs muscles weakness [13][14][15][16], Fatigue [17], Pelvic floor weakness [18][19].

In 15 percent of MG patients the symptoms remain in the area of palpebrae superioris, orbicularis oculi and oculomotor muscles and other symptoms of generalized disease doesn’t occur in them. This kind of myastehnia is OMG (ocular myasthenia gravis).(1-2-3-4-5-6 uptodate ocular)

Complications

Complications that can develop as a result of myasthenia gravis are:

Complications from the treatment of myasthenia gravis: the side effects of drugs we use in the treatment of myasthenia gravis can become very serious and reduce the quality of life in these patients.

Prognosis

The prognosis of myasthenia gravis depends on:

  • Disease duration at diagnosis: If the symptoms last less than 1 year, the patient has a 25 percent chance of going into remission by 10 years.[20]
  • Disease severity[20]
  • The age of onset: Younger patients seems to have better chance for remission than older ones.[20] Patients more than 50 years old are more prone to myasthenia crises like respiratory failure.[21]

References

  1. ↑ Alkhawajah NM, Oger J (November 2013). "Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing". Muscle Nerve. 48 (5): 705–10. doi:10.1002/mus.23964. PMID 23893883.
  2. ↑ Osher RH, Glaser JS (March 1980). "Myasthenic sustained gaze fatigue". Am. J. Ophthalmol. 89 (3): 443–5. PMID 7369304.
  3. ↑ Silvestri NJ, Wolfe GI (July 2012). "Myasthenia gravis". Semin Neurol. 32 (3): 215–26. doi:10.1055/s-0032-1329200. PMID 23117946.
  4. ↑ Keesey JC (April 2004). "Clinical evaluation and management of myasthenia gravis". Muscle Nerve. 29 (4): 484–505. doi:10.1002/mus.20030. PMID 15052614.
  5. ↑ Keesey J, Buffkin D, Kebo D, Ho W, Herrmann C (1981). "Plasma exchange alone as therapy for myasthenia gravis". Ann. N. Y. Acad. Sci. 377: 729–43. PMID 6951497.
  6. ↑ Spooner JW, Baloh RW (January 1979). "Eye movement fatigue in myasthenia gravis". Neurology. 29 (1): 29–33. PMID 570673.
  7. ↑ Lepore FE, Sanborn GE, Slevin JT (July 1979). "Pupillary dysfunction in myasthenia gravis". Ann. Neurol. 6 (1): 29–33. doi:10.1002/ana.410060107. PMID 228589.
  8. ↑ Patten BM (1978). "Myasthenia gravis: review of diagnosis and management". Muscle Nerve. 1 (3): 190–205. doi:10.1002/mus.880010304. PMID 86952.
  9. ↑ Roberts ME, Steiger MJ, Hart IK (January 2002). "Presentation of myasthenia gravis mimicking blepharospasm". Neurology. 58 (1): 150–1. PMID 11781428.
  10. ↑ De Assis JL, Marchiori PE, Scaff M (1994). "Atrophy of the tongue with persistent articulation disorder in myasthenia gravis: report of 10 patients". Auris Nasus Larynx. 21 (4): 215–8. PMID 7779022.
  11. ↑ Oosterhuis H, Bethlem J (April 1973). "Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study". J. Neurol. Neurosurg. Psychiatry. 36 (2): 244–54. PMC 1083560. PMID 4708458.
  12. ↑ Keesey JC (November 1999). "Does myasthenia gravis affect the brain?". J. Neurol. Sci. 170 (2): 77–89. PMID 10561522.
  13. ↑ Jablecki C, Benton A (1982). "The frequency of muscle involvement in myasthenia gravis correlates with mean muscle temperature". Muscle Nerve. 5 (6): 491–2. PMID 6290881.
  14. ↑ Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN (June 1982). "A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel". Ann. Neurol. 11 (6): 553–69. doi:10.1002/ana.410110603. PMID 6287911.
  15. ↑ Oh SJ, Kuruoglu R (June 1992). "Chronic limb-girdle myasthenia gravis". Neurology. 42 (6): 1153–6. PMID 1603341.
  16. ↑ Nations SP, Wolfe GI, Amato AA, Jackson CE, Bryan WW, Barohn RJ (February 1999). "Distal myasthenia gravis". Neurology. 52 (3): 632–4. PMID 10025802.
  17. ↑ Ochs CW, Bradley RJ, Katholi CR, Byl NN, Brown VM, Jones LL, Shohet JS (1998). "Symptoms of patients with myasthenia gravis receiving treatment". J Med. 29 (1–2): 1–12. PMID 9704288.
  18. ↑ Greene LF, Ghosh MK, Howard FM (August 1974). "Transurethral prostatic resection in patients with myasthenia gravis". J. Urol. 112 (2): 226–7. PMID 4843338.
  19. ↑ Wise GJ, Gerstenfeld JN, Brunner N, Grob D (August 1982). "Urinary incontinence following prostatectomy in patients with myasthenia gravis". Br J Urol. 54 (4): 369–71. PMID 6180793.
  20. ↑ 20.0 20.1 20.2 Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, Lombardi M, Mantegazza R, Monticelli ML, Piccolo G (December 1991). "Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients". J. Neurol. Sci. 106 (2): 213–20. PMID 1802969.
  21. ↑ Bever CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP (November 1983). "Prognosis of ocular myasthenia". Ann. Neurol. 14 (5): 516–9. doi:10.1002/ana.410140504. PMID 6651238.


Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Myasthenia_gravis_natural_history,_complications_and_prognosis&oldid=1478797"